Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Complex Regional Pain Syndromes
Interventions: Ketamine, Midazolam, Normal Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2099
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: Tolvaptan, Hypertonic saline infusion; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoarthritis Knee Pain
Interventions: SL1002, Normal Saline; Drug
Lead sponsor: Saol Therapeutics Inc; Industry
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 22
States / cities: Roseville, California • San Diego, California • Greenwood Village, Colorado + 19 more

Conditions: Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity, Budesonide
Interventions: Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL), Infants in the control group (S/P group) receive placebo (Normal saline 1mL); Drug
Lead sponsor: University of Arizona; Other
Eligibility: Up to 18 Hours
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Fetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and Delivery
Interventions: Lactated Ringer's; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Migraine Headache
Interventions: Auricular Acupuncture, Ketorolac 0.5mg/kg, max 30mg, Metoclopramide 0.1 mg/kg, max 10mg, Diphenhydramine 1mg/kg, max 50mg, Normal saline fluid bolus 20mL/kg, max 1000mL; Other · Drug
Lead sponsor: University of Louisville; Other
Eligibility: 8 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: Sialorrhea
Interventions: Atropine (0.01mg/kg), Glycopyrrolate (0.01mg/kg), Normal saline 0.9%; Drug
Lead sponsor: Craig J. Huang; Other
Eligibility: 6 Months to 18 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
Interventions: Avelumab, Peripheral Blood Collection, Placebo; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 9
States / cities: Orange, California • Aurora, Colorado • Tampa, Florida + 6 more

Conditions: Dysfunctional Labor
Interventions: Propranolol, IV Placebo; Drug · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Shock, Cardiogenic
Interventions: Dobutamine, Milrinone, Normal Saline; Drug
Lead sponsor: Ottawa Heart Institute Research Corporation; Other
Eligibility: 18 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lactation
Interventions: Recombinant Human Prolactin, Recombinant human prolactin, Normal Saline; Drug · Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes, Hypertension
Interventions: Rosiglitazone, Normal saline 0.9%, Intralipid 20%; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Muscle Spasticity
Interventions: botulinum toxin Type A, Normal Saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Downey, California • Daytona Beach, Florida

Conditions: Postoperative Complications
Interventions: Normal saline, Lactated Ringer's solution; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 8,616 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Dyspepsia, Healthy
Interventions: Human Secretin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer
Interventions: Tranexamic Acid, Saline; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bronchiolitis
Interventions: 3% sodium chloride, 0.9% sodium chloride; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Up to 12 Months
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis
Interventions: IV normal saline, IV immunoglobulin; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Burns
Interventions: Pathogen-Reduced Plasma, Crystalloid Solutions; Drug
Lead sponsor: Coalition for National Trauma Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee + 3 more

Conditions: Osteoarthritis
Interventions: Povidone iodine, Vancomycin powder, Conventional; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2,129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 14
States / cities: Rancho Mirage, California • Denver, Colorado • Weston, Florida + 6 more

Conditions: Osteoarthritis, Hip
Interventions: FX006, Normal saline; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 32
States / cities: Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 27 more

Conditions: Prematurity, Apnea, Respiratory Failure
Interventions: Caffeine citrate, Normal saline; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 1 Day to 5 Days
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pancreatic Cyst, EUS-FNA
Interventions: Ethanol, Normal saline, Paclitaxel + Gemcitabine admixture; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Indianapolis, Indiana • Hershey, Pennsylvania

Conditions: Renal Cell Carcinoma
Interventions: Pembrolizumab, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 62
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 52 more

Search by objective public record fields.

Ketamine and Midazolam Infusions for CRPS: Feasibility Study

Effects of Tolvaptan in Healthy Adults

Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

Pulse Pressure and Post-epidural Fetal Heart Rate Changes

Auricular Acupuncture vs SOC in Migraine HA

Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation

Adjuvant Avelumab in Merkel Cell Cancer

Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

Recombinant Human Prolactin for Lactation Induction

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes

BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

Saline Versus Lactated Ringer's Solution: The SOLAR Fluid Trial

Effect of Secretin in Functional Dyspepsia and Healthy Subjects

Impact of Topical Tranexamic Acid in Breast Reconstruction

A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis

Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

Plasma Resuscitation Without Lung Injury

Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

Caffeine to Reduce Mechanical Ventilation in Preterm Infants

CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)